Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes

Expert Review of Hematology
Andrew J Davies

Abstract

Indolent non-Hodgkin's lymphoma (iNHL) describes a group of B-cell lymphomas with a long median survival and a relapsing-remitting clinical course. Although existing treatments are initially effective, patients often relapse, demonstrating decreasing efficacy with successive treatment courses. Alternative treatments are needed. PI3Kδ plays an essential, non-redundant role in B-cell receptor signaling critical to the pathogenesis of iNHL. It is expressed predominantly in hematopoietic cells, making PI3Kδ an attractive therapeutic target. Idelalisib is an oral PI3Kδ inhibitor approved in 2014 in the USA and the EU as monotherapy in relapsed follicular lymphoma or relapsed small lymphocytic lymphoma previously treated with two or more prior systemic therapies, or as part of combination therapy with rituximab in patients with chronic lymphocytic leukemia, for whom rituximab monotherapy would be considered appropriate due to the presence of comorbidities. Herein, we review the available data for idelalisib, with an emphasis on relapsed/refractory B-cell iNHL.

References

Sep 18, 2002·The Journal of Experimental Medicine·Elizabeth ClaytonMartin Turner
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthF Anthony Greco
Jul 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert MarcusGeorge Stein
Oct 22, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Caylib A DurandMichael R Gold
Nov 3, 2009·Cell·Lakshmi SrinivasanKlaus Rajewsky
Apr 10, 2010·Nature Reviews. Molecular Cell Biology·Bart VanhaesebroeckBenoit Bilanges
Jul 27, 2011·Pharmacogenomics·Fabian Müller, Martin F Fromm
May 16, 2012·Cancer Discovery·David A Fruman, Christian Rommel
Aug 14, 2012·Frontiers in Immunology·Jose J Limon, David A Fruman
Oct 16, 2012·Blood Reviews·Matthew A Lunning, Julie M Vose
May 21, 2013·Pharmacological Reviews·Jörg KönigMartin F Fromm
Sep 18, 2013·Critical Reviews in Oncology/hematology·Audrey Thomas-SchoemannFrançois Goldwasser
Dec 10, 2013·Hematology·Nathan Fowler, Eric Davis
Jan 24, 2014·The New England Journal of Medicine·Ajay K GopalGilles A Salles
Feb 1, 2014·Nature Reviews. Drug Discovery·David A Fruman, Christian Rommel
Mar 22, 2014·Clinical Lymphoma, Myeloma & Leukemia·Jason R Westin
Apr 2, 2014·American Journal of Hematology·Arnold Freedman
Jun 14, 2014·Journal of the National Comprehensive Cancer Network : JNCCN·Andrew D ZelenetzHema Sundar
Jul 16, 2014·Current Opinion in Oncology·Emily Curran, Sonali M Smith
Aug 8, 2014·British Journal of Haematology·James S Blachly, Robert A Baiocchi
Sep 23, 2014·Pharmacology & Therapeutics·Todd M BauerJeffrey R Infante
Feb 3, 2015·Therapeutic Advances in Hematology·Valentín Ortiz-MaldonadoJulio Delgado
Feb 12, 2015·Clinical Pharmacology and Therapeutics·A RamamoorthyL Zhang
Mar 3, 2015·Leukemia & Lymphoma·Steven E CoutréAndrew D Zelenetz
Mar 12, 2015·Journal of Clinical Pharmacology·Feng JinSrini Ramanathan
Mar 31, 2015·Journal of Clinical Pharmacology·Feng JinSrini Ramanathan

❮ Previous
Next ❯

Citations

Aug 7, 2019·Clinical Pharmacokinetics·Nikki BlosserDouglas Stewart
May 26, 2018·Current Treatment Options in Oncology·Melody R Becnel, Loretta J Nastoupil
Nov 3, 2020·Clinical Lymphoma, Myeloma & Leukemia·Tycel J PhillipsVincent Ribrag

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Qingshan YangVarsha Gandhi
The New England Journal of Medicine
Ajay K GopalGilles A Salles
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Yvonne G HewettBinay K Shah
© 2021 Meta ULC. All rights reserved